M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Letrozole in Patients With Ovarian Tumors

Phase 2

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Letrozole

First Posted Date: 2007-07-23

Last Posted Date: 2012-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00505661

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Measuring Sleep Disturbance Among Cancer Patients

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: Questionnaire
Device: Actigraph

First Posted Date: 2007-07-23

Last Posted Date: 2022-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 459

Registration Number: NCT00505544

Locations: 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Gene Polymorphisms and Symptoms in Lung Cancer Patients

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-20

Last Posted Date: 2019-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 235

Registration Number: NCT00504374

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

Phase 2

Completed

Conditions: Glioblastoma Multiforme
Anaplastic Glioma of Brain
Brain Cancer

Interventions: Drug: Capecitabine
Drug: Celecoxib (Celebrex)
Drug: Temozolomide
Drug: Lomustine
Drug: 6-Thioguanine

First Posted Date: 2007-07-20

Last Posted Date: 2012-01-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT00504660

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib

First Posted Date: 2007-07-20

Last Posted Date: 2011-09-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT00504634

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients

Completed

Conditions: Myelodysplastic Syndrome
Acute Myeloblastic Leukemia
Leukemia

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-20

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00504920

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Fatigue in Emergency Center Patients

Terminated

Conditions: Hematologic Malignancy
Advanced Cancer
Fatigue

Interventions: Behavioral: Surveys

First Posted Date: 2007-07-20

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00504985

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery

Not Applicable

Completed

Conditions: Esophageal Cancer
Lung Cancer

Interventions: Behavioral: Interactive Voice Response System
Other: Symptoms Report

First Posted Date: 2007-07-20

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00505024

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Rituximab and ABVD for Hodgkin's Patients

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: Dacarbazine (DTIC)

First Posted Date: 2007-07-20

Last Posted Date: 2013-07-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 85

Registration Number: NCT00504504

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

Fibrin Melanoma Axillary Node Study in Patients With Melanoma

Not Applicable

Completed

Conditions: Melanoma

Interventions: Drug: Fibrin Sealant

First Posted Date: 2007-07-20

Last Posted Date: 2023-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 121

Registration Number: NCT00504582

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy